Source

Recombinant gene engineering production, E. coli expression.

Product introduction

Insulin degludec is a long-acting human insulin analog obtained by expressing recombinant DNA in E. coli and then undergoing chemical modification. It is structurally similar to human insulin, with the exception of a palmitic acid side chain linked to the ε-amino group of lysine at position B29 through L-γ-glutamyl, in place of the threonine at position B30 in human insulin. This side chain may bind reversibly to proteins in the body, contributing to the slow release of insulin degludec. Due to its hexameric complex release mechanism, insulin degludec has a half-life of ≥36 hours, allowing for once-daily dosing flexibility.

Product characteristics

• Source of product: E.coli
• Appearance: White or off-white powder
• Purity: ≥99%
• Quality standard: Enterprise standard (in accordance with domestic IND requirements)
• Storage conditions: Store and transport at or below -15°C
• Expiration date: Tentatively 24 months

Comparison of this product to the original peptide

Product features

• Complies with regulatory requirements: This product formulation has completed domestic IND and has obtained clinical approval. The raw material can be used for scientific research and can also be exported as a raw material for formulation. For more information, please consult us.
• Complete quality documents: With a comprehensive quality assurance system and quality documents, DMF can be applied for.
• No animal sources: Recombinant production, no exogenous viral contamination, and no animal-sourced raw materials are used in the production process.
• Quality stability: Batch production can be guaranteed stable and continuous; the difference between product batches is small and the quality is stable.

Related products（For more detailed information, please contact us）

Insulin aspart, Insulin Icodec